Summit Therapeutics Inc. - Press Release on Akeso's Approval of Ivonescimab


Subject: Summit Therapeutics announced that its partner, Akeso, Inc., received approval from the Chinese National Medical Products Administration (NMPA) for Ivonescimab for a second indication.

Clinical Trial: The approval was based on results from the Phase III clinical trial, HARMONi-2 (AK112-303).

Interim Analysis: The interim overall survival analysis reported a hazard ratio of 0.777 at 39% data maturity.